Close Menu

NEW YORK (GenomeWeb) – Taiwanese diagnostics firm PlexBio said today that it received CE marking for its IntelliPlex Lung Cancer Panel, an in vitro molecular diagnostic assay for the qualitative identification of 36 DNA mutations.

The assay can identify mutations in the KRAS, NRAS, PIK3CA, BRAF, and EGFR genes, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from formalin-fixed, paraffin-embedded tumor tissue from lung cancer patients, PlexBio said. It added that the assay leverages its SelectAmp and πCode technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.